Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2020 Filed Dec 3, 2020 23:05 UTC |
Metzger Michael ADirector · President and COO
|
SaleCommon Stock | 15,000 | $22.97 | $344,512.50 |
DisclosureSEC source: 0001562180-20-007070 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 705,824 options to purchase shares of common stock that are vested and immediately exercisable and a total of 565,416 options to purchase shares of common stock that have not yet vested. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 23:05 UTC |
Metzger Michael ADirector · President and COO
|
Exercise / conversionCommon Stock | 15,000 | $7.20 | $108,000.00 |
DisclosureSEC source: 0001562180-20-007070 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,684 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · derivative · entry 7 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,684 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,288 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · derivative · entry 6 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,288 shares Expires 2023-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
SaleCommon Stock | 16,334 | $22.89 | $373,924.46 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 5 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The sales prices ranged from $22.34 to $23.32. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
SaleCommon Stock | 7,954 | $23.58 | $187,594.29 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 4 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,334 F2 · price: The sales prices ranged from $23.35 to $23.94. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
SaleCommon Stock | 5,684 | $23.33 | $132,602.60 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,288 F1 · price: The sales prices ranged from $22.94 to $23.73. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,684 | $3.08 | $17,506.72 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:38 UTC |
Ordentlich PeterChief Scientific Officer
|
Exercise / conversionCommon Stock | 24,288 | $3.08 | $74,807.04 |
DisclosureSEC source: 0001562180-20-006920 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 17,466 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,466 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
SaleCommon Stock | 17,466 | $20.06 | $350,312.07 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,565 F3 · price: The sale prices ranged from $20.00 to $20.29. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 17,466 | $7.20 | $125,755.20 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 62,938 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,938 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
SaleCommon Stock | 62,938 | $20.04 | $1,261,264.93 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,565 F2 · price: The sale prices ranged from $20.00 to $20.21. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:55 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 62,938 | $7.20 | $453,153.60 |
DisclosureSEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The number of securities reported reflects the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC |
Metzger Michael ADirector · President and COO
|
Exercise / conversionStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC |
Metzger Michael ADirector · President and COO
|
SaleCommon Stock | 100,000 | $20.31 | $2,031,410.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 22:55 UTC |
Metzger Michael ADirector · President and COO
|
Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0001562180-20-006583 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Feb 5, 2021 21:21 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
OtherCommon Stock | 2,665 | $7.97 | $21,240.05 |
DisclosureSEC source: 0001562180-21-000931 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,395 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:11 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005074 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,730 F1 · shares: 50% of the shares will vest on July 6, 2021 and the remaining 50% of the shares will vest on July 6, 2022. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:35 UTC |
Jarrett JenniferDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001232 · primarydocument.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:37 UTC |
Shea Richard PChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,200 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · derivative · entry 3 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,200 Underlying: Common Stock · 43,200 shares Expires 2030-02-12 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:35 UTC |
Katkin KeithDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001231 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:33 UTC |
Podlesak DennisDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001228 · primarydocument.xml · derivative · entry 1 Podlesak Dennis · CIK 0001314595 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:36 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 194,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001235 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:35 UTC |
Legault PierreDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001230 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:36 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,825 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001236 · primarydocument.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,825 Underlying: Common Stock · 50,825 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:37 UTC |
Metzger Michael ADirector · President and COO
|
GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001238 · primarydocument.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-02-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:37 UTC |
Metzger Michael ADirector · President and COO
|
GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001238 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · shares: 3,750 shares shall vest on each of 02/12/2021, 02/12/2022, 02/12/2023 and 02/12/2024. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:36 UTC |
Ordentlich PeterChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001234 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:35 UTC |
Egros FabriceDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001233 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:33 UTC |
Meury WilliamDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001229 · primarydocument.xml · derivative · entry 1 Meury William · CIK 0001536778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 21:07 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
PurchaseCommon Stock | 12,500 | $8.00 | $100,000.00 |
DisclosureSEC source: 0001562180-20-000891 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,900 Read SEC document |
| January 31, 2020 Filed Feb 14, 2020 16:37 UTC |
Shea Richard PChief Financial Officer
|
OtherCommon Stock | 1,505 | $7.97 | $11,994.85 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · nonDerivative · entry 2 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,121 F2 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,505 shares by the Reporting Person on 01/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 10:33 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
PurchaseCommon Stock | 11,000 | $5.40 | $59,400.00 |
DisclosureSEC source: 0001562180-19-005140 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Read SEC document |
| July 31, 2019 Filed Feb 14, 2020 16:37 UTC |
Shea Richard PChief Financial Officer
|
OtherCommon Stock | 1,401 | $4.89 | $6,850.89 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,616 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,401 shares by the Reporting Person on 07/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 04, 2019 Filed Jul 8, 2019 20:01 UTC |
Metzger Michael ADirector · President and COO
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001562180-19-003880 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-07-04 F1 · derivative.exercise_date: The securities awarded on 07/04/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan and shall vest in 48 successive equal monthly installments measured from 07/04/2019. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC |
Jarrett JenniferDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003488 · primarydocument.xml · derivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC |
Meury WilliamDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003491 · primarydocument.xml · derivative · entry 1 Meury William · CIK 0001536778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 09:00 UTC |
Podlesak DennisDirector
|
GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003492 · primarydocument.xml · derivative · entry 1 Podlesak Dennis · CIK 0001314595 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2029-06-10 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC |
Katkin KeithDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003489 · primarydocument.xml · derivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 09:00 UTC |
Legault PierreDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003490 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 13:00 UTC |
Egros FabriceDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-19-003487 · primarydocument.xml · derivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document |
| May 13, 2019 Filed May 13, 2019 20:11 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
PurchaseCommon Stock | 7,200 | $7.29 | $52,516.80 |
DisclosureSEC source: 0001562180-19-002780 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:11 UTC |
Morrison BriggsDirector · Chief Executive Officer
|
PurchaseCommon Stock | 13,200 | $7.56 | $99,726.00 |
DisclosureSEC source: 0001562180-19-002780 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · price: The purchase prices ranged from $7.50 to $7.60. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:05 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
PurchaseCommon Stock | 104 | $4.87 | $506.48 |
DisclosureSEC source: 0001562180-19-002012 · primarydocument.xml · nonDerivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,222 Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:05 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
PurchaseCommon Stock | 1,000 | $4.93 | $4,930.00 |
DisclosureSEC source: 0001562180-19-002012 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,118 Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 20:03 UTC Amendment |
Meyers Michael L.SVP, Chief Medical Officer
|
PurchaseCommon Stock | 8 | $4.87 | $38.96 |
DisclosureSEC source: 0001562180-19-002023 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,230 F1 · shares: Amendment filed to correct previously filed Form, which did not include 8 shares purchased in an additional transaction. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:27 UTC |
Shea Richard PChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 91,200 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000854 · primarydocument.xml · derivative · entry 2 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,200 Underlying: Common Stock · 91,200 shares Expires 2029-02-06 F3 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 43,200 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 48,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC |
Ordentlich PeterChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000856 · primarydocument.xml · derivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 40,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 40,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.